Safety of lung stereotactic ablative radiotherapy for the functioning of cardiac implantable electronic devices

Highlights: • The number of patients with a CIED requiring a course of RT in increasing remarkably. • We report the first in-vivo report of thoracic SABR in patients with a CIED. • No CIEDs-dysfunctions were observed, keeping the max dose • Thoracic SABR can be safely administered to CIED-bearing patients. The prevalence of patients with a cardiac implantable device (CIED) developing cancer and requiring a course of radiotherapy (RT) is increasing remarkably. Previously published reports agree that standard and conventionally fractionated RT is usually safe for CIEDs, but no "in-vivo" reports are available on the potential effects of thoracic stereotactic ablative radiotherapy (SABR) regimens to CIEDs functioning. The purpose of our study is therefore to evaluate the effects of SABR on CIEDs (pacemakers [PM] or implantable cardiac defibrillators [ICD]) in a cohort of patients affected by primary or metastatic lung lesions.